NCT01411410 2017-10-11
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
Phase 1 Completed
Clinical Trials
3 trialsNCT00962611 2017-10-06
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT01392521 2015-04-17
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Bayer
Phase 1 Completed